CEO / Co-founder
Viewmind
ViewMind provides a digital assessment platform that uses a head‑mounted display with high‑precision eye‑tracking to capture ocular movement responses to visual stimuli. By converting eye‑movement patterns into objective biomarkers of specific cognitive domains, the system enables early detection, monitoring, and evaluation of neurocognitive health for neurology clinics, memory‑care centers, and CNS drug development programs.
- Artificial Intelligence
- Data & Analytics
- Digital Health
- Hardware
- Healthcare Technology
- Medical Devices
Updated 5 months ago
Funding
Raised to date
$8.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Neurologists and clinicians lack sensitive, non‑invasive tools to detect subtle cognitive changes early in neurodegenerative or psychiatric disorders, and existing biomarkers or neuroimaging are costly, invasive, and often only applied after symptoms appear.
Solution
ViewMind delivers a digital assessment platform that quantifies ocular movement responses to visual stimuli using a head‑mounted display with integrated eye‑tracking sensors. By phenotyping eye‑movement patterns, the system infers the functional status of specific cognitive domains and their associated brain regions. The assessment is performed quickly, requires no specialist operator, and generates objective digital biomarkers that can be used for early diagnosis, disease monitoring, and evaluation of therapeutic effects in clinical trials or routine care. Data are processed with proprietary algorithms and presented to clinicians through a secure dashboard, enabling precise, longitudinal tracking of neurocognitive health.
Target Audience
Primary customers are neurology clinics, memory‑care centers, and pharmaceutical companies conducting CNS drug development that require sensitive, repeatable measures of cognitive function.
Features
- Head‑mounted display (HMD) equipped with high‑precision eye‑tracking to capture real‑time ocular responses to calibrated visual tasks
- Automated stimulus presentation and response analysis that map eye‑movement signatures to distinct cognitive domains and brain regions
- Scalable, non‑invasive digital biomarker generation suitable for large‑scale screening and repeated measurements
- Cloud‑based analytics pipeline applying AI models to detect subtle deviations and predict disease progression
- Clinician dashboard with domain‑specific scores, trend visualizations, and exportable reports for integration into electronic health records
- Compatibility with pharmaceutical clinical trial protocols for Phase I‑IV studies assessing cognitive outcomes